Technology
Lifordi’s ADC-based delivery platform targets a cell surface protein mainly expressed on immune cells, including myeloid and lymphoid cells. The unique biologic properties of VISTA, including its rapid internalization and intracellular accumulation, make it ideal for an ADC approach. Preclinical studies of Lifordi’s lead ADC candidate, LFD-200, demonstrated a short serum half-life and long immune cell residency, as well as an ability to exert immunosuppressive function within these cells for an extended time without the toxicity associated with systemic delivery. Lifordi's ADC-based platform is also being applied to target both innate and adaptive immune cells with different payloads such as small molecules and nucleic acids. This innovative approach could offer a new way to target autoimmune and inflammatory conditions across various medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology.
